~~<i id='23B65DF89C'><strike id='23B65DF89C'><tt id='23B65DF89C'><pre id='23B65DF89C'></pre></tt></strike></i>~~

Home» explore» fashion

fashion

author：hotspot 2025-09-06 05:05:09 Page View：2

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Threats against the LGBTQIA+ community intensifying: Department of Homeland Security
Next article： In age of alternative facts, a scholarly course on calling out crap

comprehensive

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

NIH fellows want a pay raise. Will that mean less money for grants?

NIHresearchfellowswanttounionize,inlargepartbecausetheywantaraise.Willthatmeanlessmoneyforgrants?Lyd

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

Oak trusses raised to roof of fire

0:38AcraneliftsahugeoakframeatNotreDamedePariscathedral,Tuesday,July11,2023inParis.Thepanelsaredueto